|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models显示文摘AIM To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma(HCC) patients after liver transplant.METHODS BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein(AFP), Lens culinaris agglutinin-reactive AFP(AFP-L3), and des-gammacarboxyprothrombin(DCP). Pre-transplant AFP, AFP-L3 and DCP were measured in 113 patients transplanted for HCC from 2000 to 2008. Hazard ratios(HR) for recurrence and death were calculated. Univariate and multivariate regression analyses were conducted. C-statistics were used to compare biomarker-based to predictive models. RESULTS During a median follow-up of 12.2 years, 38 patients recurred and 87 died. The HRs for recurrence in patients with elevated AFP, AFP-L3, and DCP defined by BALAD cut-off values were 2.42(1.18-5.00), 1.86(0.98-3.52), and 2.83(1.42-5.61), respectively. For BALAD, the HRs for recurrence and death per unit increased score were 1.48(1.15-1.91) and 1.59(1.28-1.97). For BALAD-2, the HRs for recurrence and death per unit increased class were 1.45(1.06-1.98) and 1.38(1.09-1.76). For recurrence prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs. 0.64, 0.61, 0.53, and 0.53 for BALAD, BALAD-2, Milan, and UCSF, respectively. Similarly, for death prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs 0.65,0.61, 0.52, and 0.50 for BALAD, BALAD-2, Milan, and UCSF. A new model combining biomarkers with tumor size at the time of transplant(S-LAD) demonstrated the highest predictive capability with c-statistics of 0.71 and 0.69 for recurrence and death. CONCLUSION BALAD and BALAD-2 are valid in transplant HCC patients, but less predictive than the three biomarkers in combination or the three biomarkers in combination with maximal tumor diameter(S-LAD). | Nicha Wongjarupong Gabriela M Negron-Ocasio Roongruedee Chaiteerakij Benyam D Addissie Essa A Mohamed Kristin C Mara William S Harmsen J Paul Theobald Brian E Peters Joseph G Balsanek Melissa M Ward Nasra H Giama Sudhakar K Venkatesh Denise M Harnois Michael R Charlton Hiroyuki Yamada Alicia Algeciras-Schimnich Melissa R Snyder Terry M Therneau Lewis R Roberts | 2018 | World Journal of Gastroenterology2018，24，12： | 5 |
| 2 | Efficacy of ethanol a- gainst Candida albicans and Staphylococcus aureus polymicrobial biofilms显示文摘 | Peters B M Ward R M Rane H S | 2013 | Antimicrob Agents Chemother2013，57，1： | 1 |
| 3 | Sustainable housing applications and policies for low-income self-build and housing rehab显示文摘 | Sullivan Esther Peter M Ward | 2012 | Habitat International2012，36，： | 1 |
| 4 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Localization of Recurrent Prostate Cancer After External Beam Radiotherapy显示文摘 | Masoom A. Haider Peter Chung Joan Sweet Ants Toi Kartik Jhaveri Cynthia Ménard Padraig Warde John Trachtenberg Gina Lockwood Michael Milosevic | 2008 | International Journal of Radiation Oncology Biology Physics2008，，2： | 1 |
| 5 | Titanium alloys for aerospace applications显示文摘 | PETERS M KUMPFERT J WARD C H | 2003 | Advanced Engineering Materials2003，5，6： | 1 |
| 6 | Chemical functionalities of high and low sulfur Australian coals : A case study using micro attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectrometry 显示文摘 | Li Zhongsheng Peter M Fredericks Colin R Ward | 2010 | Organic Geochemistry2010，41，： | 1 |
| 7 | Application of attenuated total reflectance micro-Fourier transform infrared (ATR- FTIR) spectroscopy to the study of coal macerals: Examples from the Bowen Basin, Australia 显示文摘 | Li Zhongsheng Peter M Fredericks Llew Rintoul Colin R Ward | 2007 | International Journal of Coal Geology2007，70，13： | 1 |
| 8 | Tita- nium Alloys for Aerospace Applications 显示文摘 | PETERS M KUMPFERT J WARD C H LEYENS C | 2003 | Engineering Material2003，5，6： | 1 |
| 9 | How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?显示文摘In the last 15 years the management of inflammatory bowel disease has evolved greatly,largely through the increased use of immunomodulators and,especially,anti-tumor necrosis factor(anti-TNF) biologic agents. Within this time period,confidence in the use of anti-TNFs has increased,whilst,especially in recent years,the efficacy and safety of thiopurines has been questioned. Yet despite recent concerns regarding the risk: benefit profile of thiopurines,combination therapy with an immunomodulator and an anti-TNF has emerged as the recommended treatment strategy for the majority of patients with moderate-severe disease,especially those who are recently diagnosed. Concurrently,therapeutic drug monitoring has emerged as a means of optimizing the dosage of both immunomodulators and antiTNFs. However the recommended therapeutic target levels for both drug classes were largely derived from studies of monotherapy with either agent,or studies underpowered to analyze outcomes in combination therapy patients. It has been assumed that these target levels are applicable to patients on combination therapy also,however there are few data to support this. Similarly,the timing and duration of treatment with immunomodulators when used in combination therapy remains unknown. Recent attention,including post hoc analyses of the pivotal registration trials,has focused on the optimization of anti-TNF agents,when used as either monotherapy or combination therapy. This review will instead focus on how best to optimize immunomodulators when used in combination therapy,including an evaluation of recent data addressing unanswered questions regarding the optimal timing,dosage and duration of immunomodulator therapy in combination therapy patients. | Mark G Ward Peter M Irving Miles P Sparrow | 2015 | World Journal of Gastroenterology2015，21，40： | 1 |
| 10 | Transitional Strategies for Alternative FuelSupply Infrastructure: Moving from Fuel Flexible to Dedicated Vehicles显示文摘 | Jonathan M Teague Peter F Ward | 1995 | AlternativeFuel1995，，： | 1 |
| 11 | Ti- tanium alloys for aerospace applications 显示文摘 | PETERS M KUMPFERT J WARD C H | 2003 | Ad- vanced Engineering Materials2003，5，6： | 1 |
| 12 | Efficacy of ethanol against Candida albicans and Staphylococcus aureus polymicrobial biofilms 显示文摘 | Peters B M Ward R M Rane H S | 2013 | Antimicrob Agents Chemother2013，57，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员